Evidence method
Level · gp.fundamentals.debt_to_revenue
103.82% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ARQT · Mar 31, 2026
Arcutis Biotherapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001787306-26-000040General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.00% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
2.12% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
60.07% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
35.48% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
90.72% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-8.62% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
29.06% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
10.14% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History10 statesHistory building
Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/9 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20240/8 normalizedLevel 3Mar 31, 20250/9 normalizedLevel 3Jun 30, 20250/9 normalizedLevel 3Sep 30, 20250/9 normalizedLevel 3Dec 31, 20257/9 normalizedLevel 3Mar 31, 20268/9 normalizedLevel 3Jun 30, 20268/9 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 28.97%
- Current
- 103.82%
- Delta
- 74.84%
- Previous
- 0.18%
- Current
- 0.00%
- Delta
- -0.18%
- Previous
- -1.50%
- Current
- 2.12%
- Delta
- 3.62%
- Previous
- 91.34%
- Current
- 60.07%
- Delta
- -31.28%
- Previous
- 6.02%
- Current
- 35.48%
- Delta
- 29.46%
- Previous
- 90.24%
- Current
- 90.72%
- Delta
- 0.47%
- Previous
- -3.25%
- Current
- -8.62%
- Delta
- -5.37%
- Previous
- 20.49%
- Current
- 29.06%
- Delta
- 8.57%
- Previous
- 10.73%
- Current
- 10.14%
- Delta
- -0.59%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ARQT Fundamental State →Has State · Arcutis Biotherapeutics, Inc. →Transitioned To · ARQT Fundamental State →Transitioned To · ARQT BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · ARQT CAPEX_INTENSITY_DECREASED →Transitioned To · ARQT CASH_GENERATION_INCREASED →Transitioned To · ARQT GROWTH_DECREASED →Transitioned To · ARQT INVENTORY_PRESSURE_INCREASED →Transitioned To · ARQT MARGIN_INCREASED →Transitioned To · ARQT PROFITABILITY_DECREASED →Transitioned To · ARQT R_AND_D_INTENSITY_INCREASED →Transitioned To · ARQT SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.